AC Immune Company
AC Immune is a Swiss biopharmaceutical company that focuses on developing therapeutic and diagnostic products for neurodegenerative diseases caused by misfolding proteins. They have three product candidates in clinical trials and two proprietary technology platforms that create antibodies, small molecules, and vaccines for a broad range of neurodegenerative indications. AC Immune is a global leader in precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Connections
Investors Number:
2
Total Funding:
117439497
Technology:
Therapeutic and Diagnostics
Estimated Revenue:
$10M to $50M
Employee Number:
51-100
Industry:
BioTech
Founded Date:
2003
Headquarters:
Lausanne, Vaud
Last Funding Date:
09 05 16
Last Funding Type:
Series E
Funding Status:
IPO